-+ 0.00%
-+ 0.00%
-+ 0.00%

NFL Biosciences flags CESTO2 post-hoc analysis on NFL-101 smoking-cessation biomarker at SFT congress

PUBT·09/08/2026 06:30:35
Listen to the news
NFL Biosciences flags CESTO2 post-hoc analysis on NFL-101 smoking-cessation biomarker at SFT congress
  • NFL Biosciences set an oral presentation on a post-hoc CESTO2 analysis for NFL-101 at the SFT congress on Sept. 24-25, 2026.
  • Results were previously selected for poster presentation at SRNT-Europe 2026 in Paris on Sept. 21-23, 2026.
  • Work points to baseline IgG1 levels as a potential predictor of which smokers are more likely to benefit from NFL-101.
  • The biomarker approach could sharpen patient targeting, supporting a personalized strategy that may influence the program’s clinical development path.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NFL Biosciences SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260907278975) on September 08, 2026, and is solely responsible for the information contained therein.